WO2016108638A1 - 재조합 당단백질의 글리코실화 조절 방법 - Google Patents
재조합 당단백질의 글리코실화 조절 방법 Download PDFInfo
- Publication number
- WO2016108638A1 WO2016108638A1 PCT/KR2015/014512 KR2015014512W WO2016108638A1 WO 2016108638 A1 WO2016108638 A1 WO 2016108638A1 KR 2015014512 W KR2015014512 W KR 2015014512W WO 2016108638 A1 WO2016108638 A1 WO 2016108638A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- insulin
- recombinant glycoprotein
- glycans
- recombinant
- protein
- Prior art date
Links
- 102000003886 Glycoproteins Human genes 0.000 title claims abstract description 67
- 108090000288 Glycoproteins Proteins 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims abstract description 30
- 230000013595 glycosylation Effects 0.000 title claims description 14
- 238000006206 glycosylation reaction Methods 0.000 title claims description 13
- 230000001105 regulatory effect Effects 0.000 title abstract description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 98
- 102000004877 Insulin Human genes 0.000 claims abstract description 49
- 108090001061 Insulin Proteins 0.000 claims abstract description 49
- 229940125396 insulin Drugs 0.000 claims abstract description 49
- 235000000346 sugar Nutrition 0.000 claims abstract description 31
- 238000012258 culturing Methods 0.000 claims abstract description 16
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 16
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 16
- 239000002157 polynucleotide Substances 0.000 claims abstract description 16
- 239000002609 medium Substances 0.000 claims description 27
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 108010008165 Etanercept Proteins 0.000 claims description 21
- 108060003951 Immunoglobulin Proteins 0.000 claims description 15
- 102000018358 immunoglobulin Human genes 0.000 claims description 15
- 244000005700 microbiome Species 0.000 claims description 15
- 102000037865 fusion proteins Human genes 0.000 claims description 7
- 108020001507 fusion proteins Proteins 0.000 claims description 7
- 230000012010 growth Effects 0.000 claims description 7
- 230000004988 N-glycosylation Effects 0.000 claims description 6
- 230000004989 O-glycosylation Effects 0.000 claims description 5
- 230000010412 perfusion Effects 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 35
- 108090000623 proteins and genes Proteins 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 15
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 14
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 14
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 11
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102100040247 Tumor necrosis factor Human genes 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- -1 asparagine amino acid Chemical class 0.000 description 7
- 230000001276 controlling effect Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 229960001031 glucose Drugs 0.000 description 6
- 229920001542 oligosaccharide Polymers 0.000 description 6
- 150000002482 oligosaccharides Chemical class 0.000 description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229960000403 etanercept Drugs 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 150000002772 monosaccharides Chemical class 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 235000019743 Choline chloride Nutrition 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 101000801232 Homo sapiens Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 2
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 2
- 229960003178 choline chloride Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- MVFCKEFYUDZOCX-UHFFFAOYSA-N iron(2+);dinitrate Chemical compound [Fe+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O MVFCKEFYUDZOCX-UHFFFAOYSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- HOZBSSWDEKVXNO-BXRBKJIMSA-N (2s)-2-azanylbutanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CC(O)=O HOZBSSWDEKVXNO-BXRBKJIMSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 1
- 235000000638 D-biotin Nutrition 0.000 description 1
- 239000011665 D-biotin Substances 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical group O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LVXHNCUCBXIIPE-UHFFFAOYSA-L disodium;hydrogen phosphate;hydrate Chemical compound O.[Na+].[Na+].OP([O-])([O-])=O LVXHNCUCBXIIPE-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940076153 heptahydrate zinc sulfate Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- SZQUEWJRBJDHSM-UHFFFAOYSA-N iron(3+);trinitrate;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O SZQUEWJRBJDHSM-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 229940074478 monohydrate dibasic sodium phosphate Drugs 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 150000004686 pentahydrates Chemical class 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000007739 pm medium Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/18—Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/10—Biofuels, e.g. bio-diesel
Definitions
- the present invention relates to a method for controlling glycosylation of recombinant glycoprotein.
- Etanercept is a TNFR-Fc fusion protein that connects the ligand binding portion of the human p75 TNF- ⁇ receptor (TNFR, TNF- ⁇ receptor) to the Fc fragment of human IgGI. Enbrel).
- Etanercept inhibits the TNF- ⁇ -related immune response by competitively inhibiting the binding of TNF- ⁇ receptors and TNF- ⁇ on the cell surface in the body.
- etanercept is used as a TNF- ⁇ inhibitor for rheumatoid arthritis, psoriasis, ankylosing spondylitis, etc., and clinical studies are under way for application to vasculitis, Alzheimer's disease and Crohn's disease.
- genetic recombination drug refers to a drug using a peptide or protein produced using genetic engineering techniques as an active ingredient.
- Biotechnology has the advantage of obtaining a large amount of high purity recombinant protein, which is difficult to obtain in nature, but the expression construct itself may be unstable because the gene of the target protein is inserted into the host cell from the outside.
- recombinant proteins may differ from natural proteins in structural, physicochemical, immunochemical, and biological properties or properties because they are expressed by microorganisms, copper, and plant cells other than the human body to produce proteins (Kwon Oh-seok et al., FDC). Legal Research, Vol. 5, No. 1, 2, 13-21, 2010).
- glycoproteins whether glycosylation is present and the structure or form of the oligosaccharide may vary depending on the type of host cell, a method of recombining recombinants, and culture conditions. That is, in the production of glycoproteins, various kinds of glycoforms are generated depending on the structure of the sugar chain or the amount of sugars constituting the sugar chain, and thus heterogeneity may exist due to the difference in production conditions. Glycoproteins with different sugar chain structures may have different in vivo kinetics or tissue distribution from their natural forms, or may antagonize their natural forms, causing harmful reactions, or acting as antigens for prolonged continuous administration, causing immunological problems. have.
- Korean Patent Laid-Open Publication No. 2011-0139292 describes the control of protein glycosylation and related compositions and methods
- Korean Patent Publication No. 2012-0134116 increases the occupancy of N-glycosylation sites on therapeutic glycoproteins. It describes about the method to make it.
- the present inventors have made intensive studies to develop a method for regulating glycosylation of recombinant glycoproteins. As a result, the present inventors have confirmed that the glycosylation pattern of recombinant glycoproteins can be controlled when a medium containing insulin is used. .
- It is a main object of the present invention to provide a method of controlling a glycosylation pattern of a recombinant glycoprotein comprising culturing a microorganism comprising a polynucleotide encoding the recombinant glycoprotein in a medium containing insulin.
- Another object of the present invention is a growth step of culturing and growing a microorganism comprising a polynucleotide encoding a recombinant glycoprotein in a culture medium; And (b) to provide a method for controlling the sugar chain pattern of the recombinant glycoprotein comprising the production step of producing a glycoprotein by culturing by adding insulin to the medium.
- the method of controlling sugar chain pattern of the recombinant glycoprotein according to the present invention may control activity, folding, secretion, stability, plasma half-life and immune response of the recombinant glycoprotein.
- 1 shows a cleavage map of pCUCBin-mSig-TNFcept.
- Figure 2 shows the number of viable cells (unit 10 5 cells / ml) and the survival rate (%) according to the cell culture time (unit: day) in one embodiment of the present invention.
- the present invention comprises the step of culturing a microorganism comprising a polynucleotide encoding a recombinant glycoprotein in a medium containing insulin, glycosylation pattern of the recombinant glycoprotein Provides a way to control
- glycoprotein refers to a protein in which a sugar binds to a specific amino acid of a polypeptide
- the sugar may refer to, for example, a sugar chain in which one or two monosaccharides are linked.
- the oligosaccharide is an oligosaccharide in which various monosaccharides are linked to glycoproteins, and monosaccharides such as fucose, N-acetylglucosamine, N-acetylgalactosamine, galactose, mannose and sialic acid, glucose and xyl acid. Ozone, mannose-6-phosphate, or a branched form thereof, and the like.
- the recombinant glycoprotein may be an immunoglobulin fusion protein.
- the immunoglobulin is a heavy chain constant region 2 (CH2), a heavy chain constant region, except for the variable regions of the heavy and light chains of immunoglobulin (Ig), except for the heavy chain constant region 1 (CH1) and the light chain constant region (CL1) It may comprise an Fc that is part of an immunoglobulin comprising a (CH3) and a hinge portion.
- the recombinant glycoprotein may be a TNFR-Fc fusion protein.
- the tumor necrosis factor receptor refers to a receptor protein that binds to TNF- ⁇ .
- the TNFR protein includes both a TNFRI (p55) protein or a TNFRII (p75) protein, preferably a TNFRII protein, but is not limited thereto.
- the TNFRII may be mixed with Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B).
- TNFRSF1B Tumor necrosis factor receptor superfamily member 1B
- the TNFRII protein is divided into four domains and a transmembrane region.
- the TNFRII protein may be a TNFRII protein including four domains consisting of 235 amino acids and a membrane passing region, but is not limited thereto.
- TNFRI protein and TNFRII protein may be obtained from a known database such as the National Institute of Health GenBank, for example, but may be a protein having an Accession number of NP_001056 or P20333, but is not limited thereto.
- the TNFR protein Since the TNFR protein has an activity of binding to TNF- ⁇ , which is known to cause various diseases when overexpressed in the human body, it can be used for the treatment of diseases mediated by TNF- ⁇ such as autoimmune diseases.
- the Fc region of an immunoglobulin may be manufactured and used in the form of a fusion protein having an increased half-life by fusion to a TNFR protein.
- the tumor necrosis factor receptor (TNFR) -Fc fusion protein is a product in which all or part of the TNFR protein is linked to an Fc region of an immunoglobulin by enzymatic action, or the two polypeptides are expressed as one polypeptide through genetic manipulation. Means.
- the TNFR-Fc fusion protein may be directly connected to the TNFR protein and the Fc region of an immunoglobulin or through a peptide linker, but is not limited thereto.
- Non-limiting examples of the TNFR-Fc fusion protein may include etanercept (US patent 7,915,225; 5,605,690; Re. 36,755).
- the TNFR-Fc fusion protein may be prepared by fusion of all or a portion of the TNFR protein with an immunoglobulin Fc region, for example, an immunoglobulin Fc region including amino acid positions 1 to 235 and a hinge region of the TNFRII protein. 232 amino acids of may be fused, but is not limited thereto.
- the TNFR-Fc fusion protein may be codon optimized according to the host cell to be expressed, for example, it may be a TNFR-Fc fusion protein codon optimized specifically for CHO cells, but is not limited thereto. .
- the TNFR-Fc fusion protein is at least 70%, preferably at least 80%, more preferably at least 90%, even more preferably at least 95%, most preferably 98% of the amino acid sequence as well as the sequence.
- amino acid sequence showing the above similarity any protein having an activity that substantially binds TNF- ⁇ is included.
- sequence having such similarity is an amino acid sequence having the same or corresponding biological activity as the TNFR-Fc fusion protein
- protein variants having an amino acid sequence of which some sequences are deleted, modified, substituted or added are also within the scope of the present invention. Inclusion is self-evident.
- the Fc is a heavy chain constant region 2 (CH2), a heavy chain constant region (except for the regions except for the heavy and light chain variable regions, heavy chain constant region 1 (CH1) and light chain constant region (CL1) of immunoglobulin (img) CH3) and a portion of an immunoglobulin including the hinge portion.
- the Fc region of the present invention includes naturally occurring amino acid sequences as well as sequence derivatives thereof. Amino acid sequence derivatives mean that one or more amino acid residues in a naturally occurring amino acid sequence have different sequences by deletion, insertion, non-conservative or conservative substitution, or a combination thereof.
- the immunoglobulin Fc region may be an Fc region derived from IgG, IgM, IgE, IgA or IgD, or a combination thereof, or a hybrid thereof. It is preferably derived from IgG known to improve the half-life of the binding protein, more preferably derived from IgG1 or obtained from any subclass (ie IgG1, IgG2, IgG3 and IgG4).
- the Fc region may be obtained by genetically engineering a gene encoding the Fc region by using a recombinant vector or by cleaving with a suitable protein cleavage enzyme such as papain or pepsin from a purified polyclonal antibody or a monoclonal antibody.
- a suitable protein cleavage enzyme such as papain or pepsin from a purified polyclonal antibody or a monoclonal antibody.
- the TNFR-Fc fusion protein can be obtained by introducing into an host cell an expression vector comprising a polynucleotide encoding the fusion protein.
- the pCUCBin-mSig-TNFcept vector was used as an expression vector comprising a polynucleotide encoding a TNFR-Fc fusion protein, which was transduced into CHO cells and expressed the TNFR-Fc fusion protein.
- the microorganism may be used in the same sense as the host cell or transformant.
- Non-limiting examples can be animal cell lines, plants or yeast hosts.
- CHO cells Choinese Hamster Ovarian ovary cells
- the present invention is not limited thereto as long as they can be mutated to the polynucleotide encoding the recombinant glycoprotein.
- the polynucleotide may include all of them, as long as the polynucleotide can be expressed in a microorganism, whether it is inserted into or located outside a chromosome of a microorganism.
- the polynucleotide includes DNA and RNA encoding a target protein.
- the method of including the polynucleotide can be used without limitation so long as it is a method used in the art.
- the gene may be included in a microorganism in the form of an expression cassette, which is a gene construct including all elements necessary for self-expression.
- a method of mutating by an expression vector comprising a nucleotide sequence of the polynucleotide encoding the target protein operably linked to a suitable control sequence to express the target protein in a suitable host
- the regulatory sequence includes a promoter capable of initiating transcription, any operator sequence for regulating such transcription, a sequence encoding a suitable mRNA ribosomal binding site, and a sequence regulating termination of transcription and translation.
- the vector After being transformed into a suitable host cell, the vector can be replicated or function independent of the host genome and integrated into the genome itself.
- the expression vector is not particularly limited as long as it is replicable in a host cell, and any vector known in the art may be used.
- the glycosylation pattern of the recombinant glycoprotein refers to the expression of oligosaccharides expressed through glycosylation of glycoproteins.
- the presence or absence of glycosylation binding to the protein, the type of sugar, the type of glycosylation, the content of sugar, the composition of the monosaccharide (component sugar) including the molar ratio, the position of the oligosaccharide, the structure of the oligosaccharide including the sequence, the glycosylation site, the sugar It may include the mole share, the number of sugar chains, or the relative content of each structure.
- it may cause a difference in bioactivity or in vivo stability.
- insulin may be to regulate N-linked glycosylation of recombinant glycoproteins.
- the N-linked glycosylation may be used in the same sense as N-glycosylation.
- the insulin may be to reduce the content of N-glycans of the recombinant glycoprotein.
- the N-glycan may be used in the same sense as the N-glycan chain, and may refer to a case where a sugar binds to an asparagine amino acid of a protein.
- insulin may be one that regulates O-linked glycosylation of recombinant glycoproteins.
- the O-linked glycosylation may be used in the same sense as O-glycosylation.
- the insulin may be to reduce the content of O-glycans of the recombinant glycoprotein.
- the O-glycan may be used in the same sense as the O-sugar chain, and may mean a case where a sugar is bound to a serine or threonine amino acid of a protein.
- Insulin in the present invention may be to regulate the N-linked sugar chaining and O-linked sugar chaining of the recombinant glycoprotein.
- the addition of insulin has been shown to affect the sugar chain pattern of glycoproteins (Table 2).
- the content of N-glycans and / or O-glycans has been shown to change with the addition of insulin.
- the content of N-glycans and / or O-glycans can be adjusted according to the addition of insulin.
- the addition of insulin is important for glycemic pattern control in the production stage.
- the concentration of insulin may be from 0.0001 mg / L to 1 g / L with respect to the total medium volume. In one embodiment of the present invention, it was confirmed that the content of N-glycans and / or O-glycans can be adjusted to decrease with increasing concentration of insulin (Table 2).
- the medium may be used without limitation as long as it is used to culture microorganisms or host cells including polynucleotides encoding glycoproteins in the art.
- the medium is glutamic acid (L-Glutamine), thymidine (Thymidine), alanine (Alanine), arginine (Arginine, monohydrochloride), asparagine (Asparagine, monohydrate), aspartic acid (Aspartic acid), Cysteine (Cysteine) Glycine, Histidine, Isoleucine, Leucine, Lysine, monohydrochloride, Methionine, Phenylalanine, Proline, Serine, Threonine It may include amino acids such as Threonine, Tryptophan, Tyrosine (Tyrosine, disodium salt, dehydrate), Valine (Valine).
- the medium is glucose (Glucose), sodium bicarbonate (Sodium bicarbonate), sodium chloride (Sodium chloride), calcium chloride (Calcium chloride, ananhydrous), cupric sulfate (pentahydrate), iron (II) nitrate (II) Ferric nitrate, nonahydrate, Ferrous sulfate, heptahydrate, Potassium chloride, Magnesium sulfate, ananhydrous, Magnesium chloride, ananhydrous, Sodium phosphate, monobasic or dibasic, monohydrate, zinc sulfate, heptahydrate, hypoxanthine, putrescine, dihydrochloride, sodium pyruvate, biotin, calcium pantothenate (D- Calcium pantothenate, Choline Chloride, Cyanocobalamin, Folic acid, i-Inositol, Nicotinamide, Pyridoxal, monohydrochloride, Pyridoxine oxi
- the culture may be a perfusion culture.
- the culturing may mean culturing while flowing a culture solution around the microorganism. Through the perfusion culture, the concentration of insulin can be easily adjusted according to the desired sugar chain pattern.
- the present invention provides a growth step of (a) culturing a microorganism comprising a polynucleotide encoding a recombinant glycoprotein in a culture medium; And (b) a production step of culturing by adding insulin to the medium to produce a glycoprotein.
- the recombinant glycoprotein may be an immunoglobulin fusion protein.
- the recombinant glycoprotein may be a TNFR-Fc fusion protein. This is as described above.
- the growth step of step (a) may further comprise a species culture step.
- the medium of step (a) may not include insulin.
- Step (b) may be to add the insulin concentration differently according to the desired sugar chain pattern.
- the content of N-glycans and / or O-glycans has been shown to change with the addition of insulin at the growth stage. Specifically, it was confirmed that the content of N-glycans and / or O-glycans can be adjusted according to the addition of insulin. In particular, during the culturing of cells capable of producing glycoproteins, it was confirmed that the addition of insulin is important for glycemic pattern control in the production stage.
- the concentration of insulin may be from 0.0001mg / L to 1g / L with respect to the total medium volume. It was confirmed that the concentration of N-glycans and / or O-glycans could be adjusted to decrease with increasing concentration of insulin (Table 2).
- Insulin may be one that regulates N-linked glycosylation and O-linked glycosylation of recombinant glycoproteins.
- the insulin may be to reduce the content of N-glycans of the recombinant glycoprotein.
- the insulin may be to reduce the content of O-glycans of the recombinant glycoprotein.
- the present invention provides a medium composition for controlling a sugar chain pattern of a recombinant glycoprotein comprising insulin.
- the insulin may be included at 0.0001 mg / L to 1 g / L with respect to the whole medium.
- the medium may be used only in the production step of the culture step of the microorganism.
- TNFR Human p75 TNF receptor
- CHO / dhfr- (CHO DXB11) was used as the parent cell.
- CHO / dhfr- is a cell deficient in Dihydrofolate Reductase (DHFR) gene after isolation from Chinese Hamster ovary cells.
- DHFR Dihydrofolate Reductase
- the pCUCBin-mSig-TNFcept vector containing the P75 TNF receptor (TNFR) gene and CHO / dhfr- (CHO DXB11) were used to make transformed cells and amplified the gene using MTX concentration. Among them, candidates satisfying the criteria were selected and evaluated as monoclonal and selected as production cell lines. The cell lines were then placed in glass bottles and stored in liquid nitrogen.
- the medium used for the culture was used differently depending on the culture step.
- Media X011SB Merck Millipore, Cat.No. 102443
- (Sigma) 0.584 g / l of medium (Media EC-SI) was used, and in the growth phase (Growth Phase) 5 g / l of anhydrous glucose and 0.584 g / l of L-Glutamine, Glycine, and Serine, respectively, were added.
- the medium (EC-GM) was used, and in the production phase, 15 g / l of anhydrous glucose and 0.584 g / l of L-Glutamine, Glycine, and Serine were used (EC-PM).
- the vial containing the cell line prepared in Example 1 was quickly thawed in a water bath, and the cells were transferred to a Falcon Tube containing 10 mL of medium. Thereafter, the supernatant was first removed by centrifugation. After resuspending with 10 mL of Media EC-SI, the final volume was inoculated in Erlenmeyer Flask so that the final volume was 50 mL.
- the exchange was started with EC-GM medium through perfusion culture. As the number of cells increased, the rate of medium exchange was increased to allow the cells to differentiate well.
- the viable cell number reached 1.5 ⁇ 10 7 cells / mL (FIG. 2)
- the medium was exchanged with EC-PM medium to move from the growth stage to the production stage. The harvest was carried out four times in total, and the recovered protein was purified. The results were calculated as four averages.
- Example 2 The sample purified in Example 2 was prepared by diluting with 25 mM Sodium Phosphate, pH 6.3 buffer to 100 ⁇ l at 1.0 mg / mL concentration. Each sample contains 4 ⁇ l of N-glycosidase F (1U / ⁇ l, Roche), 1 ⁇ l of Neuraminidase (1U / 100 ⁇ l, Roche), trypsin (1 mg / mL, Promega) 2 ⁇ l was added to react at 37 ° C. for 18 hours and LC-MS analysis was performed.
- Example 2 The sample and standard (Etanercept, Pfizer) purified in Example 2 was prepared by diluting with a sample diluent (25 mM Sodium Phosphate, pH 6.3 buffer) to 3.0 mg / mL, respectively. 100 ⁇ l of each sample and 6 ⁇ l of N-glycosidase F solution were mixed and reacted at 37 ° C. for 20 hours. 400 ⁇ l of ethanol was added to the finished solution and vortexed. After centrifugation, only the supernatant was taken and transferred to an Eppendorf tube, and the solution was completely dried using a Speed-Vac Concentrator. 10 ⁇ l of 2-AA labeling agent was added to the dried sample and mixed. After the reaction at 45 °C cooled to room temperature.
- a sample diluent 25 mM Sodium Phosphate, pH 6.3 buffer
- the GlycoClean S cartridge (Cartridge) was placed on a disposable culture tube, and then purified water, 30% acetic acid, and acetonitrile were flowed in this order. The chilled sample was then loaded into the membrane center of the cartridge and then acetonitrile was flowed. To elute N-glycan, purified water was added to the cartridge and collected in the Eppendorf Tube. The resulting aqueous solution of Glycan was lyophilized and stored until analysis.
- the sugar chain pattern of the glycoproteins according to the addition of insulin in the production step of Example 2 is shown in Table 2 below.
- the addition of insulin at the production stages was shown to affect the glycoprotein pattern of the glycoproteins.
- the content of N-glycans and / or O-glycans has been shown to change with the addition of insulin.
- the content of N-glycans and / or O-glycans can be adjusted according to the addition of insulin.
- the method of controlling sugar chain patterns of recombinant glycoproteins according to the present invention can change the content of N-glycans and / or O-glycans according to the addition of insulin at the growth stage, and thus, in particular, the uniformity of the binding of sugar molecules It can be usefully used in the production of recombinant glycoproteins for important pharmaceuticals.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Marine Sciences & Fisheries (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
배양온도(생산단계) | Harvest(회차) | N-glycan -2 charge (%, 평균) | O-glycopeptide의 상대 면적비 (%, 평균) |
30oC | H1 | 12.5 | 56.13 |
H2 | |||
H3 | |||
H4 | |||
32oC | H1 | 16.1 | 54.38 |
H2 | |||
H3 | |||
H4 |
배양온도 | 배지 내인슐린 농도 | Harvest(회차) | N-glycan -2 charge (%, 평균) | O-glycopeptide의 상대 면적비 (%, 평균) |
30oC | 0mg/L | H1 | 12.5 | 56.13 |
H2 | ||||
H3 | ||||
H4 | ||||
0.003mg/L | H1 | 10.4 | 54.68 | |
H2 | ||||
H3 | ||||
H4 | ||||
0.009mg/L | H1 | 10.9 | 52.68 | |
H2 | ||||
H3 | ||||
H4 | ||||
0.03mg/L | H1 | 9.7 | 49.5 | |
H2 | ||||
H3 | ||||
H4 |
Claims (15)
- 재조합 당단백질을 코딩하는 폴리뉴클레오티드를 포함하는 미생물을 인슐린을 포함하는 배지에서 배양하는 단계를 포함하는, 재조합 당단백질의 당쇄 패턴(glycosylation pattern)을 조절하는 방법.
- 제1항에 있어서,상기 재조합 당단백질은 면역글로불린 융합 단백질인 것인, 방법.
- 제1항에 있어서,상기 재조합 당단백질은 TNFR-Fc 융합 단백질인 것인, 방법.
- 제1항에 있어서,상기 인슐린의 농도는 전체 배지 부피에 대하여 0.0001mg/L 내지 1g/L 인 것인, 방법.
- 제1항에 있어서,상기 인슐린은 재조합 당단백질의 N-연결 당쇄화(N-linked glycosylation) 및 O-연결 당쇄화(O-linked glycosylation)를 조절하는 것인, 방법.
- 제1항에 있어서,상기 인슐린은 재조합 당단백질의 N-글리칸의 함량을 감소시키는 것인, 방법.
- 제1항에 있어서,상기 인슐린은 재조합 당단백질의 O-글리칸의 함량을 감소시키는 것인, 방법.
- 제1항에 있어서,상기 배양은 관류 배양인 것인, 방법.
- (a) 배양 배지에서 재조합 당단백질을 코딩하는 폴리뉴클레오티드를 포함하는 미생물을 배양하여 성장시키는 성장 단계; 및(b) 상기 배지에 인슐린을 첨가하여 배양하여 당단백질을 생산하는 생산 단계를 포함하는, 재조합 당단백질의 당쇄 패턴을 조절하는 방법.
- 제9항에 있어서,상기 (b) 생산 단계는 목적하는 당쇄 패턴에 따라 인슐린 농도를 다르게 첨가하는 것인, 방법.
- 제10항에 있어서,상기 인슐린은 재조합 당단백질의 N-글리칸 또는 O-글리칸의 함량을 감소시키는 것인, 방법.
- 제9항에 있어서,상기 재조합 당단백질은 면역글로불린 융합 단백질인 것인, 방법.
- 제9항에 있어서,상기 재조합 당단백질은 TNFR-Fc 융합 단백질인 것인, 방법.
- 제9항에 있어서,상기 인슐린의 농도는 전체 배지 부피에 대하여 0.0001mg/L 내지 1g/L 인 것인, 방법.
- 제9항에 있어서,상기 배양은 관류 배양인 것인, 방법.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017535399A JP6502505B2 (ja) | 2014-12-31 | 2015-12-30 | 組換え糖タンパク質のグリコシル化の調節方法 |
RU2017124160A RU2670889C9 (ru) | 2014-12-31 | 2015-12-30 | Способ контроля гликозилирования рекомбинантного гликопротеина |
MX2017008634A MX2017008634A (es) | 2014-12-31 | 2015-12-30 | Metodo para controlar la glicosilacion de glicoproteina recombinante. |
IL253217A IL253217B (en) | 2014-12-31 | 2015-12-30 | A method for controlling the glycosylation of a recombinant glycoprotein |
EP15875732.8A EP3241908B1 (en) | 2014-12-31 | 2015-12-30 | Method for regulating glycosylation of recombinant glycoprotein |
US15/541,123 US10131891B2 (en) | 2014-12-31 | 2015-12-30 | Method of using insulin for controlling glycosylation of recombinant glycoprotein |
BR112017014252A BR112017014252A2 (pt) | 2014-12-31 | 2015-12-30 | método para o controle de glicosilação de glicoproteína recombinante |
AU2015372704A AU2015372704B2 (en) | 2014-12-31 | 2015-12-30 | A method for controlling glycosylation of recombinant glycoprotein |
SA517381863A SA517381863B1 (ar) | 2014-12-31 | 2017-07-04 | طريقة للتحكم في معالجة بالسكر لبروتين سكر تخليقي |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140195976A KR102007930B1 (ko) | 2014-12-31 | 2014-12-31 | 재조합 당단백질의 글리코실화 조절 방법 |
KR10-2014-0195976 | 2014-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016108638A1 true WO2016108638A1 (ko) | 2016-07-07 |
Family
ID=56284687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/014512 WO2016108638A1 (ko) | 2014-12-31 | 2015-12-30 | 재조합 당단백질의 글리코실화 조절 방법 |
Country Status (11)
Country | Link |
---|---|
US (1) | US10131891B2 (ko) |
EP (1) | EP3241908B1 (ko) |
JP (1) | JP6502505B2 (ko) |
KR (1) | KR102007930B1 (ko) |
AU (1) | AU2015372704B2 (ko) |
BR (1) | BR112017014252A2 (ko) |
IL (1) | IL253217B (ko) |
MX (1) | MX2017008634A (ko) |
RU (1) | RU2670889C9 (ko) |
SA (1) | SA517381863B1 (ko) |
WO (1) | WO2016108638A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999061650A1 (en) * | 1998-05-29 | 1999-12-02 | Genentech, Inc. | Cell culture process for producing glycoproteins |
KR20090029841A (ko) * | 2006-07-13 | 2009-03-23 | 와이어쓰 | 당단백질의 생산 |
KR20110139292A (ko) * | 2009-04-20 | 2011-12-28 | 화이자 인코포레이티드 | 단백질 글리코실화의 제어 및 그와 관련된 조성물 및 방법 |
US20120276631A1 (en) * | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
WO2015026846A1 (en) * | 2013-08-19 | 2015-02-26 | Biogen Idec Ma Inc. | Control of protein glycosylation by culture medium supplementation and cell culture process parameters |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5705364A (en) * | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
JPH0947284A (ja) * | 1995-08-07 | 1997-02-18 | Sumitomo Pharmaceut Co Ltd | 動物細胞の培養方法 |
US7294481B1 (en) | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
EP1487479B1 (en) | 2001-10-22 | 2012-06-20 | Merck Serono SA | Mutant glycoproteins |
US7300773B2 (en) | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
WO2007034809A1 (ja) * | 2005-09-20 | 2007-03-29 | Taisho Pharmaceutical Co., Ltd. | 組み換え蛋白質産生のための宿主細胞 |
AU2006324163B2 (en) | 2005-12-08 | 2013-05-02 | Amgen Inc. | Improved production of glycoproteins using manganese |
TW201516149A (zh) * | 2006-09-13 | 2015-05-01 | Abbvie Inc | 細胞培養改良 |
AU2008223133A1 (en) | 2007-03-02 | 2008-09-12 | Wyeth | Use of copper and glutamate in cell culture for production of polypeptides |
CN102216459A (zh) * | 2008-09-15 | 2011-10-12 | 弗·哈夫曼-拉罗切有限公司 | 调节细胞摩尔渗透压浓度的组合物和方法 |
US20120329709A1 (en) | 2009-05-26 | 2012-12-27 | Brian Edward Collins | Production of glycoproteins |
EP2534255B1 (en) * | 2010-02-10 | 2017-05-10 | Biocon Limited | Method of reducing glycosylation of proteins, processes and proteins thereof |
MX2012009802A (es) | 2010-02-24 | 2012-09-12 | Merck Sharp & Dohme | Metodo para incrementar la ocupacion del sitio de n-glucosilacion en glucoproteinas terapeuticas producidas en pichia pastoris. |
KR101868139B1 (ko) | 2010-11-30 | 2018-06-15 | 주식회사 엘지화학 | 새로운 융합 프로모터 및 이를 포함하는 재조합 벡터 |
SI2837680T1 (sl) * | 2011-07-01 | 2020-07-31 | Amgen Inc. | Celična kultura sesalca |
KR102202476B1 (ko) | 2013-03-15 | 2021-01-12 | 제넨테크, 인크. | 세포 배양 배지 및 항체 생산 방법 |
WO2014195452A1 (en) | 2013-06-07 | 2014-12-11 | Novo Nordisk A/S | Method for making mature insulin polypeptides |
US20160237399A1 (en) * | 2015-02-18 | 2016-08-18 | Biogen Ma Inc. | Control of Protein Glycosylation by Culture Medium Supplementation and Cell Culture Process Parameters |
-
2014
- 2014-12-31 KR KR1020140195976A patent/KR102007930B1/ko active IP Right Grant
-
2015
- 2015-12-30 EP EP15875732.8A patent/EP3241908B1/en not_active Revoked
- 2015-12-30 RU RU2017124160A patent/RU2670889C9/ru active
- 2015-12-30 MX MX2017008634A patent/MX2017008634A/es unknown
- 2015-12-30 BR BR112017014252A patent/BR112017014252A2/pt active Search and Examination
- 2015-12-30 AU AU2015372704A patent/AU2015372704B2/en active Active
- 2015-12-30 IL IL253217A patent/IL253217B/en unknown
- 2015-12-30 JP JP2017535399A patent/JP6502505B2/ja active Active
- 2015-12-30 WO PCT/KR2015/014512 patent/WO2016108638A1/ko active Application Filing
- 2015-12-30 US US15/541,123 patent/US10131891B2/en active Active
-
2017
- 2017-07-04 SA SA517381863A patent/SA517381863B1/ar unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999061650A1 (en) * | 1998-05-29 | 1999-12-02 | Genentech, Inc. | Cell culture process for producing glycoproteins |
KR20090029841A (ko) * | 2006-07-13 | 2009-03-23 | 와이어쓰 | 당단백질의 생산 |
KR20110139292A (ko) * | 2009-04-20 | 2011-12-28 | 화이자 인코포레이티드 | 단백질 글리코실화의 제어 및 그와 관련된 조성물 및 방법 |
US20120276631A1 (en) * | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
WO2015026846A1 (en) * | 2013-08-19 | 2015-02-26 | Biogen Idec Ma Inc. | Control of protein glycosylation by culture medium supplementation and cell culture process parameters |
Non-Patent Citations (2)
Title |
---|
BIOL-N'GARAGBA, MARIE - CLAIRE ET AL.: "Regulation of the Intestinal Glycoprotein Glycosylation during Postnatal Development: Role of Hormonal and Nutritional Factors", BIOCHIMIE, vol. 85, 2003, pages 331 - 352, XP055460873 * |
See also references of EP3241908A4 * |
Also Published As
Publication number | Publication date |
---|---|
IL253217A0 (en) | 2017-08-31 |
US20170342392A1 (en) | 2017-11-30 |
AU2015372704B2 (en) | 2018-09-20 |
KR20160081699A (ko) | 2016-07-08 |
EP3241908A4 (en) | 2018-06-20 |
AU2015372704A1 (en) | 2017-07-20 |
SA517381863B1 (ar) | 2020-06-23 |
MX2017008634A (es) | 2018-04-26 |
IL253217B (en) | 2022-08-01 |
JP6502505B2 (ja) | 2019-04-17 |
US10131891B2 (en) | 2018-11-20 |
KR102007930B1 (ko) | 2019-08-06 |
EP3241908B1 (en) | 2020-08-05 |
EP3241908A1 (en) | 2017-11-08 |
RU2670889C1 (ru) | 2018-10-25 |
BR112017014252A2 (pt) | 2018-01-02 |
JP2018500041A (ja) | 2018-01-11 |
RU2670889C9 (ru) | 2018-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100496356B1 (ko) | 포유동물세포배양으로생산되는단백질의시알릴화조절방법 | |
US10881741B2 (en) | Single chain Fc fusion proteins | |
US6927043B2 (en) | Interleukin-2 mutein expressed from mammalian cells | |
EP2119727B1 (en) | Method for production of recombinant human FSH | |
US20230287101A1 (en) | Production of Biosimilar Ustekinumab in CHO Cells | |
Moran et al. | A systematic approach to the validation of process control parameters for monoclonal antibody production in fed‐batch culture of a murine myeloma | |
Ha et al. | Knockout of sialidase and pro-apoptotic genes in Chinese hamster ovary cells enables the production of recombinant human erythropoietin in fed-batch cultures | |
ES2261740T3 (es) | Composiciones de fsh con alto grado de sialilacion y su uso para la preparacion de medicamentos. | |
US10557115B2 (en) | Medium containing uridine and N-acetyl-D-mannosamine | |
US20070099266A1 (en) | Process for the production of tumor necrosis factor-binding proteins | |
WO2016108638A1 (ko) | 재조합 당단백질의 글리코실화 조절 방법 | |
Ozgur et al. | Therapeutic proteins: A to Z | |
US20220324934A1 (en) | Designed il-2 variants | |
CN112074537A (zh) | 具有经调节的聚糖谱的抗体 | |
WO2017078451A1 (ko) | 재조합 인간 갑상선 자극 호르몬을 포함하는 조성물 및 상기 재조합 인간 갑상선 자극 호르몬의 생산 방법 | |
NZ752502B2 (en) | A Method For Controlling Glycosylation Of Recombinant Glycoprotein | |
NZ733430A (en) | A method for controlling glycosylation of recombinant glycoprotein | |
NZ752502A (en) | A Method For Controlling Glycosylation Of Recombinant Glycoprotein | |
Nguyen | Engineering of Chinese hamster host cell line | |
WO2017078453A1 (ko) | 재조합 인간 갑상선 자극 호르몬을 포함하는 조성물 및 상기 재조합 인간 갑상선 자극 호르몬의 정제 방법 | |
Gardner et al. | Use of recombinant DNA technology in ART |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15875732 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2017/008634 Country of ref document: MX Ref document number: 253217 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017/09518 Country of ref document: TR |
|
ENP | Entry into the national phase |
Ref document number: 2017535399 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15541123 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017014252 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2015372704 Country of ref document: AU Date of ref document: 20151230 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015875732 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017124160 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112017014252 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170629 |